CONCORD BIOTECH LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,467 INR | -1.28% |
|
+1.22% | -0.33% |
Valuation
| Fiscal Period: March | 2024 | 2025 | 2026 |
|---|---|---|---|
| Capitalization 1 | 1,55,465 | - | - |
| Enterprise Value (EV) 1 | 1,59,100 | 1,52,780 | 1,51,500 |
| P/E ratio | 51.6 x | 39.8 x | 31.1 x |
| Yield | 0.42% | 0.67% | 0.84% |
| Capitalization / Revenue | 15.6 x | 12.5 x | 10.2 x |
| EV / Revenue | 15.6 x | 12.3 x | 9.97 x |
| EV / EBITDA | 36.9 x | 28.6 x | 22.5 x |
| EV / FCF | 170 x | 57.6 x | 47 x |
| FCF Yield | 0.59% | 1.74% | 2.13% |
| Price to Book | 10.2 x | 8.53 x | 7.05 x |
| Nbr of stocks (in thousands) | 1,04,616 | - | - |
| Reference price 2 | 1,486 | 1,486 | 1,486 |
| Announcement Date | 24/05/24 | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net sales 1 | - | 10,169 | 12,453 | 15,192 |
| EBITDA 1 | - | 4,316 | 5,344 | 6,728 |
| EBIT 1 | - | 3,780 | 4,814 | 6,159 |
| Operating Margin | - | 37.17% | 38.65% | 40.54% |
| Earnings before Tax (EBT) 1 | - | 4,126 | 5,137 | 6,580 |
| Net income 1 | 2,401 | 3,081 | 3,913 | 5,002 |
| Net margin | - | 30.3% | 31.42% | 32.93% |
| EPS 2 | 22.95 | 29.45 | 37.38 | 47.72 |
| Free Cash Flow 1 | - | 911.5 | 2,655 | 3,223 |
| FCF margin | - | 9.19% | 21.32% | 21.22% |
| FCF Conversion (EBITDA) | - | 21.56% | 49.68% | 47.91% |
| FCF Conversion (Net income) | - | 30.29% | 67.84% | 64.43% |
| Dividend per Share 2 | - | 6.280 | 9.900 | 12.53 |
| Announcement Date | 01/07/23 | 24/05/24 | - | - |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net Debt 1 | - | - | - | - |
| Net Cash position 1 | - | 630 | 2,685 | 3,965 |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow 1 | - | 912 | 2,655 | 3,223 |
| ROE (net income / shareholders' equity) | - | 21.4% | 22.9% | 24.4% |
| ROA (Net income/ Total Assets) | - | 19% | 20% | 22% |
| Assets 1 | - | 15,837 | 19,566 | 22,739 |
| Book Value Per Share 2 | - | 146.0 | 174.0 | 211.0 |
| Cash Flow per Share | - | - | - | - |
| Capex 1 | - | 1,433 | 550 | 600 |
| Capex / Sales | - | 14.45% | 4.42% | 3.95% |
| Announcement Date | 01/07/23 | 24/05/24 | - | - |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1,486
INR
Average target price
1,592
INR
Spread / Average Target
+7.13%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -0.33% | 1.86B | |
| +0.99% | 91.72B | |
| 0.00% | 39.44B | |
| -8.52% | 34.47B | |
| +65.59% | 26.7B | |
| -17.37% | 15.13B | |
| -5.99% | 13.27B | |
| -10.69% | 11.74B | |
| -47.78% | 10.54B | |
| +8.09% | 9.41B |
- Stock Market
- Equities
- CONCORDBIO Stock
- Financials Concord Biotech Limited
